Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06701890
Recruiting Not applicable

Observational Study of Travellers Pathologies

NCT06701890 · tracked via the Priya Life Science France tracker
Sponsor
Institut Pasteur
Phase
Not applicable
Started
2024-12-09
Last updated
2025-05-01

Condition(s) studied

Travel-Related Illness

Investigational drug(s) / intervention(s)

Blood sample collectionFecal sample collection

Blood sample collection: 16 mL at inclusion 16 mL at 1 month after return from travel

Fecal sample collection: 1 sample at inclusion 1 sample at day 1, day 7, day 14, day 21, 1 month and 2 month after return from travel

Study summary

Traveling to emerging countries is associated with a significant risk of encountering health issues specific to the destination, such as gastrointestinal and respiratory infections, malaria episodes, and road traffic accidents.These conditions are associated with behavioral, geographical, or environmental risk factors. A better understanding of these factors will enable the development of targeted recommendations to minimize travel related health issues.

The main objective of this study is to determine the incidence of pathologies occurring during travel outside the metropolitan territory.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
1. Inclusion Criteria : 1. For all participants in the EOP study : * Major subject (age ≥ 18) * Owns a smartphone compatible with electronic data collection * Preparing to travel outside mainland France * Affiliated with or covered by Social Security or private insurance * Willing to participate in the EOP study 2. For the EOP-Arbo Sub-study : \- Subject who has consented to participate in the EOP\_Arbo study. 3. For the EOP-AMR Sub-study : * Subject who has consented to participate in the EOP\_AMR study. 2. Exclusion Criteria: 1. For all participants in the EOP study : * Travel duration ≤ 3 days * Travel duration \> 12 months * Person traveling as part of an expatriation without planned movement outside the settlement in the destination country * Person under legal protection or unable to express consent for participation 2. For the EOP-Arbo Sub-study : \- Individuals deemed clinically and/or biologically unfit by the investigator to undergo the blood samples required for the study. 3. For the EOP-AMR Sub-study : * No specific exclusion criteria.

Primary outcome measure(s)

  • Determine the incidence of pathologies occurring during a travel outside the metropolitan territory. — 10 years
    Number of subjects who developed a pathology during the travel among participants

Trial sites (1)

FacilityCityRegionStatus
Medical Center of Institut Pasteur Paris France Recruiting

More Institut Pasteur trials in France

Development of a Battery of Audiological Tests for the Precision Diagnosis of Age-related Hearing Loss Recruiting
The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis Recruiting
Study of Auditory Perception After Progressive Exposure to Aversive Sounds in People With Misophonia Starting soon
A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever Recruiting
Description of the Immune Response to Yellow Fever Vaccination Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06701890 on ClinicalTrials.gov ↗ ← All trials in France